S&P 500
5,970.50
+0.0%
+$0.13
DJI
42,507.04
-0.0%
-$12.60
NASDAQ
19,414.65
+0.1%
+$15.69
Bitcoin
105,317.00
-1.1%
-1,207.84
AAPL
$202.80
-0.2%
-$0.47
AMZN
$206.49
+0.4%
+$0.78
GOOG
$168.20
+0.3%
+$0.49
META
$681.00
+2.1%
+$14.15
MSFT
$463.86
+0.2%
+$0.89
NVDA
$140.50
-0.5%
-$0.72
TSLA
$332.03
-3.6%
-$12.24
Mineralys Therapeutics (NASDAQ: MLYS)
$15.92
(-1.6%)
-$0.26
Price as of June 4, 2025, 12:14 p.m. ET
Mineralys Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Mineralys Therapeutics Company Info
Mineralys Therapeutics, Inc. s a clinical-stage biopharmaceutical company engaged in developing medicines to target disease, driven by abnormally elevated aldosterone. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
News & Analysis
No articles found.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.